Denali Therapeutics (DNLI) Form 3: Director reports no ownership
Denali Therapeutics (DNLI) reported an insider Form 3 for a board member.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Denali Therapeutics (DNLI) reported an insider Form 3 for a board member. The filing identifies the reporting person as a Director and indicates it is filed by one reporting person. The event date is 11/04/2025. In the remarks, the filer states no securities are beneficially owned. The signature block shows execution on 11/06/2025 by attorney-in-fact.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Denali Therapeutics (DNLI) file?
What is the insider’s relationship to DNLI?
How many reporting persons are on this Form 3?
What is disclosed about ownership?
What is the date of the event requiring this filing?
What is the issuer and ticker?
AI-generated analysis. How Rhea-AI works. Not financial advice.